pyrroles has been researched along with delgocitinib in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 18 (72.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amano, W; Kabashima, K; Matsushita, M; Miyachi, Y; Nakajima, S; Tanimoto, A; Yamamoto, Y | 1 |
| Amano, W; Hayashi, M; Kakimoto, K; Katsuda, Y; Kimoto, Y; Konishi, N; Shinozaki, Y; Taniai-Riya, E; Tanimoto, A; Toyoda, K; Yamamoto, Y | 1 |
| Igarashi, A; Nagata, T; Nakagawa, H; Nemoto, O | 1 |
| Bissonnette, R | 1 |
| Nagata, T; Nakagawa, H; Nemoto, O; Ninomiya, N; Yamada, H | 1 |
| Sato, S; Suga, H | 1 |
| Igarashi, A; Kabashima, K; Nagata, T; Nakagawa, H; Nemoto, O; Oda, M; Saeki, H | 2 |
| Bauer, A; Elsner, P; Mahler, V; Molin, S; Nielsen, TSS; Worm, M | 1 |
| Igarashi, A; Kaino, H; Murata, R; Nagata, T; Nakagawa, H; Nemoto, O; Saeki, H | 1 |
| Amano, W; Egawa, G; Hamada, Y; Hayashi, M; Honda, T; Ishida, Y; Kabashima, K; Konishi, N; Matsushita, M; Nakashima, C; Otsuka, A; Tanimoto, A; Usui, K; Wada, M; Yamamoto, Y | 1 |
| Igarashi, A; Kaino, H; Nagata, T; Nakagawa, H; Nemoto, O; Saeki, H | 1 |
| Dhillon, S | 1 |
| Adachi, T; Doi, S; Hara, Y; Hase, Y; Hashimoto, H; Hori, A; Inoue, M; Kimoto, Y; Maeda, K; Miura, T; Negoro, T; Noji, S; Obika, S; Ogawa, Y; Oki, C; Orita, T; Shiozaki, M; Tanimoto, A; Yamamoto, H; Yamanaka, H | 1 |
| Anagawa-Nakamura, A; Ryoke, K; Shoda, T; Sugai, S; Yasui, Y | 1 |
| Kadono, T; Kishi, A; Mitsuishi, S; Miyagaki, T; Miyano, K; Nakajima, K; Okano, T; Takeuchi, S | 1 |
| Ishida, Y; Kabashima, K; Otsuka, A; Yagi, K | 1 |
| Gong, Y; Qi, F; Zhang, J; Zhou, S; Zhu, B | 1 |
| Dainichi, T; Izumi, M; Kaku, Y; Kataoka, K | 1 |
| Deguchi, N; Kawamura, T; Mitsui, H; Muto, Y; Ogawa, Y; Shimada, S | 1 |
| Fujiyama, T; Honda, T; Kurihara, K; Tokura, Y | 1 |
| Ho, J; Molin, S | 1 |
| Agner, T; Bauer, A; Ehst, B; Korn, S; Resen, K; Schliemann, S; Shi, VY; Thyssen, JP; Tillmann, S; Worm, M | 1 |
| Hide, M; Kamegashira, A; Morioke, S; Murakami, E; Numata, T; Saito, R; Suehiro, M; Takahagi, S; Takahashi, M; Tanaka, A | 1 |
| Fujimoto, RFT; Fujiwara, S; Miura, H; Takata, M | 1 |
4 review(s) available for pyrroles and delgocitinib
| Article | Year |
|---|---|
Novel topical and systemic therapies in atopic dermatitis.
Topics: Acrylamides; Administration, Topical; Antibodies, Monoclonal, Humanized; Biological Products; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Dermatitis, Atopic; Humans; Immunotherapy; Interleukin-13; Janus Kinase Inhibitors; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Pyridines; Pyrimidines; Pyrroles; Resorcinols; Stilbenes; TRPV Cation Channels | 2019 |
Delgocitinib: First Approval.
Topics: Animals; Autoimmune Diseases; Drug Approval; Humans; Hypersensitivity; Janus Kinase Inhibitors; Janus Kinases; Molecular Conformation; Pyrroles | 2020 |
Biological Therapies for Atopic Dermatitis: A Systematic Review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azetidines; Biological Products; Carbamates; Clinical Trials as Topic; Dermatitis, Atopic; Dermatologic Agents; Heterocyclic Compounds, 3-Ring; Humans; Nitriles; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2021 |
Delgocitinib in atopic dermatitis.
Topics: Child, Preschool; Dermatitis, Atopic; Humans; Janus Kinase Inhibitors; Pyrroles; Quality of Life | 2021 |
8 trial(s) available for pyrroles and delgocitinib
| Article | Year |
|---|---|
Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Dermatitis, Atopic; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ointments; Pruritus; Pyrroles; Treatment Outcome; Young Adult | 2018 |
Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
Topics: Administration, Cutaneous; Adult; Dermatitis, Atopic; Dermatitis, Phototoxic; Female; Healthy Volunteers; Humans; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Ointments; Patch Tests; Placebos; Pruritus; Pyrroles; Severity of Illness Index; Skin; Treatment Outcome; Young Adult | 2018 |
Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis.
Topics: Adolescent; Child; Child, Preschool; Dermatitis, Atopic; Double-Blind Method; Female; Humans; Male; Ointments; Pyrroles | 2019 |
Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study.
Topics: Dermatologic Agents; Double-Blind Method; Eczema; Humans; Ointments; Pyrroles; Treatment Outcome | 2020 |
Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
Topics: Acne Vulgaris; Adolescent; Adult; Dermatitis, Atopic; Dermatitis, Contact; Drug Administration Schedule; Female; Folliculitis; Humans; Incidence; Janus Kinase Inhibitors; Japan; Male; Nasopharyngitis; Ointments; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2020 |
Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Topics: Adult; Dermatitis, Atopic; Dermatologic Agents; Double-Blind Method; Female; Humans; Janus Kinase Inhibitors; Male; Ointments; Pyrroles; Treatment Outcome; Young Adult | 2020 |
Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study.
Topics: Adult; Child; Dermatitis, Atopic; Double-Blind Method; Eczema; Emollients; Humans; Ointments; Pyrroles; Treatment Outcome | 2021 |
The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
Topics: Adult; Dermatitis, Atopic; Double-Blind Method; Eczema; Emollients; Humans; Immunoglobulin A; Janus Kinase Inhibitors; Pain; Pruritus; Pyrroles; Severity of Illness Index; Treatment Outcome | 2022 |
13 other study(ies) available for pyrroles and delgocitinib
| Article | Year |
|---|---|
JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation.
Topics: Administration, Oral; Animals; Antigen Presentation; Cell Differentiation; Cell Movement; Cell Proliferation; Croton Oil; Dendritic Cells; Dermatitis, Allergic Contact; Drug Evaluation, Preclinical; Female; Haptens; Inflammation; Interferon-gamma; Interleukin-13; Interleukin-17; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Pyrroles; Skin; T-Lymphocytes | 2016 |
A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents.
Topics: Animals; Cyclosporine; Cytokines; Dermatitis, Atopic; Female; Haptens; Humans; Immunoglobulin E; Inflammation; Interleukin-23; Interleukin-23 Subunit p19; Janus Kinase Inhibitors; Male; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrroles; Rats; Rats, Inbred BN; Skin; Thymic Stromal Lymphopoietin | 2018 |
JAK inhibitors appear to have a bright future in the treatment of atopic dermatitis.
Topics: Adult; Dermatitis, Atopic; Eczema; Humans; Janus Kinase Inhibitors; Pyrroles | 2018 |
Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.
Topics: Administration, Cutaneous; Animals; Antipruritics; Dermatitis, Atopic; Disease Models, Animal; Female; Humans; Janus Kinase Inhibitors; Male; Mice; Pruritus; Pyrroles; Skin | 2020 |
Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.
Topics: Dermatitis, Atopic; Dermatologic Agents; Drug Design; Humans; Inhibitory Concentration 50; Janus Kinase Inhibitors; Janus Kinases; Models, Molecular; Protein Conformation; Pyrroles | 2020 |
Effects of Delgocitinib Ointment 0.5% on the Normal Mouse Skin and Epidermal Tight Junction Proteins in Comparison With Topical Corticosteroids.
Topics: Adrenal Cortex Hormones; Animals; Mice; Mice, Inbred ICR; Ointments; Pyrroles; Tight Junction Proteins | 2020 |
A case of facial redness in atopic dermatitis occurring during dupilumab treatment successfully treated with topical delgocitinib ointment.
Topics: Antibodies, Monoclonal, Humanized; Dermatitis, Atopic; Humans; Ointments; Pyrroles; Treatment Outcome | 2021 |
Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib.
Topics: Adult; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Vitiligo | 2021 |
Successful treatment of severe blepharitis in a patient with atopic dermatitis by topical delgocitinib.
Topics: Administration, Topical; Blepharitis; Dermatitis, Atopic; Dermatologic Agents; Humans; Janus Kinase 1; Male; Pyrroles; Treatment Outcome; Young Adult | 2021 |
Case of cutaneous sarcoidosis treated with delgocitinib 0.5% ointment.
Topics: Emollients; Humans; Ointments; Pyrroles; Sarcoidosis; Skin Diseases | 2021 |
Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment.
Topics: Administration, Topical; Adult; Antibodies, Monoclonal, Humanized; Dermatitis, Atopic; Dermatologic Agents; Drug Eruptions; Humans; Interleukin-4 Receptor alpha Subunit; Male; Ointments; Pyrroles; Treatment Outcome; Young Adult | 2021 |
Real-world efficacy of proactive maintenance treatment with delgocitinib ointment twice weekly in adult patients with atopic dermatitis.
Topics: Adult; Dermatitis, Atopic; Dermatologic Agents; Emollients; Glucocorticoids; Humans; Ointments; Pyrroles; Treatment Outcome | 2022 |
Indeterminate cell histiocytosis treated with 0.5% delgocitinib ointment.
Topics: Histiocytosis; Humans; Ointments; Pyrroles | 2023 |